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In this report, we examined the abilities and requirements of heterologous Gag proteins to functionally complement each other to support viral
replication. Two distantly related gammaretroviruses, murine leukemia virus (MLV) and spleen necrosis virus (SNV), were used as a model
system because SNV proteins can support MLV vector replication. Using chimeric or mutant Gag proteins that could not efficiently support MLV
vector replication, we determined that a homologous capsid (CA) domain was necessary for the functional complementation of MLV and SNV
Gag proteins. Findings from the bimolecular fluorescence complementation assay revealed that MLV and SNV Gag proteins were capable of
colocalizing and interacting in cells. Taken together, our results indicated that MLV and SNV Gag proteins can interact in cells; however, a
homologous CA domain is needed for functional complementation of MLVand SNV Gag proteins to complete virus replication. This requirement
of homologous Gag most likely occurs at a postassembly step(s) of the viral replication.
Published by Elsevier Inc.Keywords: Retroviruses; Capsid; Infectivity; Coassembly; Complementation; Phenotypic mixingIntroduction
All retroviruses carry at least three genes – gag, pol, and
env – encoding proteins essential for viral replication. These
genes were first translated as polyproteins and then processed
into mature proteins. The gag gene, which encodes the structural
proteins, is first translated to a Gag polyprotein and then cleaved
by the viral protease into smaller mature proteins during or soon
after virus assembly. Although Gag polyproteins from different
retroviruses may have only limited sequence homology, they
share conserved domains that are organized similarly. Gag
polyproteins from all of the retroviruses contain matrix (MA),
capsid (CA), and nucleocapsid (NC) domains, arranged in the
same order from the N to C terminus. In addition to these three
domains, Gag polyproteins from different viruses often have
other domains, located either between the three conserved
domains or at the C terminus of the polyproteins. For example,
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respectively. Human immunodeficiency virus type 1 (HIV-1)
has an additional p2 domain between CA and NC, and two
additional domains (p1 and p6) downstream from NC.
During virus assembly, Gag is targeted to the assembly sites,
coordinates the incorporation of other viral proteins and viral
RNA, and interacts with the host cell machinery for proper
release of the viral particle (Freed, 2002; Gottlinger, 2001;
Swanstrom andWills, 1997). Therefore, Gag plays a central role
in virus assembly. Even in the absence of all other viral com-
ponents, Gag or a portion of Gag can form virus-like particles in
both cultured cells and in vitro reactions (Campbell and Rein,
1999; Campbell and Vogt, 1997; Gheysen et al., 1989; Got-
tlinger, 2001; Morikawa et al., 1999; Wills and Craven, 1991).
In addition to assembly defects, mutations in gag can cause
defects in virion maturations, reverse transcription, and integra-
tion (Cairns and Craven, 2001; Forshey et al., 2002; Fu et al.,
2006; Oshima et al., 2004; Tang et al., 2001; von Schwedler et
al., 2003). The NC proteins have well-known functions in the
processes of reverse transcription and integration, because
mutations in NC can cause defects in these processes (Buckman
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Mutations in the MLV p12, Rous sarcoma virus (RSV) CA, and
HIV-1 CA can cause defects in generating reverse transcription
products (Cairns and Craven, 2001; Forshey et al., 2002; Tang et
al., 2001; von Schwedler et al., 2003; Yuan et al., 1999).
Additionally, mutations in MLV p12 can cause defects in step(s)
leading to integration (Yuan et al., 2002, 1999). In this
phenotype, reverse transcription products were generated and
preintegration complexes isolated from the infected cells were
capable of the integration reaction in vitro; however, the viruses
appeared to have defects in integration (Yuan et al., 2002).
Therefore, these studies indicated that Gag products play
important roles in the early events in the virus replication cycle.
During the past decade, it was demonstrated that functional
Gag chimeras could be generated with domains from distantly
related viruses, indicating that a Gag domain could be
functionally replaced by a sequence-divergent counterpart
from another retrovirus. For example, various functional and
nonfunctional Gag chimeras have been generated between MLV
and HIV-1 (Berkowitz et al., 1995; Chen et al., 2001; Deminie
and Emerman, 1993; Yamashita and Emerman, 2004; Zhang
and Barklis, 1995), RSV and MLV (Dupraz and Spahr, 1992),
RSV and HIV-1 (Bennett et al., 1993; Parent et al., 1995), and
SNVand MLV (Certo et al., 1999; Fu and Hu, 2003; Lee et al.,
2005). One of the most dramatic examples of a functional
chimera is RSV Gag in which the p2b domain was replaced by
the HIV-1 p6 domain (Parent et al., 1995). RSV p2b and HIV-1
p6 do not share significant sequence homology and are located
in different positions in Gag; it was later demonstrated that the
PPPY motif in p2b and the PTAP motif in p6 interact with
different cellular proteins in the same endosomal sorting
pathway to enable proper virion release (Demirov et al., 2002;
Garrus et al., 2001; Kikonyogo et al., 2001; Pornillos et al.,
2002). In different studies, the definition of the functional
chimeras varied; some of these chimeras have been shown to
generate virions or to package viral RNA, whereas others have
been shown to support one or limited rounds of viral replication.
The fact that functional Gag chimeras can be generated
indicated that the assembly pathways of different viruses might
share many similarities, which raises the questions of whether
Gag polyproteins from different retroviruses can coassemble
into the same virus and if coassembly occurs, whether viruses
containing Gag proteins from two different viruses can be
infectious. When proteins from two viruses are present in the
same virions, it is unclear whether heterologous Gag proteins
can functionally complement or interfere with each other.
Coassembly of heterologous Gag proteins was investigated
using RSVand MLV Gag (Bennett and Wills, 1999; Craven and
Parent, 1996). It was found that the unmodified RSV and MLV
Gag did not coassemble; however, these two Gag polyproteins
could coassemble when both Gag polyproteins contained the
membrane-targeting signal from the Src oncoprotein (Bennett
and Wills, 1999). This study demonstrated that there are barriers
to coassembly of heterologous Gag polyproteins; in this
particular pair, the step of membrane targeting is the barrier. In
another study, it was suggested that MLV and HIV-1 Gag
polyproteins do not coassemble because MLV Gag did notcrosslink to HIV-1 Gag (Hansen and Barklis, 1995). Using
imaging analyses, it was recently reported that a homologous
CA domain is required for coassembly of HIV-1 and RSV Gag
proteins (Ako-Adjei et al., 2005). It was observed that although
HIV-1 Gag and RSV Gag do not colocalize and coassemble, if
one of the Gag polyprotein was modified to contain the CA
domain of the other Gag, these two proteins could colocalize and
coassemble. Because gag-expression constructs were used in
the aforementioned MLV/RSV and HIV-1/RSV systems, the
potential infectivity of these mixed virions could not be
determined. Therefore, it is not known whether these mixed
particles will encounter other blocks in viral replication.
In this study, we examined whether Gag polyproteins from
two distantly related retroviruses can functionally complement
each other to complete virus replication. In order for
complementation to occur, heterologous Gag proteins need to
be coassembled and functionally assist each other. We selected
MLV, a murine virus, and SNV, an avian virus, for the following
reasons. First, the Gag polyproteins of these two viruses contain
only limited (36%) amino acid sequence identity. Second,
despite the limited homology, SNV proteins can support MLV
vector replication (Certo et al., 1998; Embretson and Temin,
1987); this feature allows us to examine the infectivity of the
coassembled virions. Third, functional Gag chimeras can be
generated between MLV and SNV (Certo et al., 1999; Fu and
Hu, 2003; Lee et al., 2005); this attribute allows us to further
pursue the barrier to functional complementation if MLV and
SNV Gag polyproteins fail to do so. Using this system, we
found that coexpression of mutant MLV and SNV Gag
polyproteins did not produce infectious virions. However,
Gag chimeras containing homologous CA domains were able to
coassemble and produce infectious virions. Therefore, the CA
domain plays a critical role in the functional complementation
of MLV and SNV Gag polyproteins.
Results
Strategy and system used to study domain(s) in Gag important
for functional complementation of heterologous Gag proteins
Both MLV and SNV proteins can package and support the
replication of MLV vectors. Using this feature, we examined
whether MLV vector replication can be supported by coexpres-
sion of various MLV or SNV gag–pol mutants or chimeras.
Individually, these mutants or chimeric gag–pol expression
constructs cannot efficiently support MLV vector replication; a
significant increase in the MLV vector titer upon coexpression
of two gag–pol constructs would indicate coassembly and
functional complementation of two gag–pol products. To take
this approach, we constructed multiple chimeras and also used
previously described mutants or chimeras. We selected gag–pol
mutants or chimeras based on the following criteria. First, these
chimeras or mutants should express Gag at a level detectable by
Western analyses. Additionally, these chimeras or mutants
should have a deficiency in supporting MLV vector replication
that would yield a minimal 1000-fold decrease in vector titer
compared with that of the MLV gag–pol expression construct.
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described pWZH30 or pRD136 (Martinez and Dornburg, 1995;
Zhang et al., 2002), which express MLVor SNV Gag/Gag–Pol,
respectively. These expression constructs contain large dele-
tions of the packaging signals and their RNAs are not
efficiently packaged by viral proteins. The general structures
of these constructs are shown in Fig. 1A. For the chimeras, one
or more Gag domains were replaced by the counterpart from
the other virus. The names of the constructs reflect the com5-
position of the sequences: the first letter after p indicates
whether the construct is based on MLV (M) or SNV (S), and the
letter following the slash indicates the heterologous domain(s)
from the other virus. For example, pM/Sp18 is an MLV-based
construct with the SNV p18 domain replacing the MLV p12
domain. In addition to the chimeras, two Gag mutants were also
used: pWZH35 and pSΔPY. pWZH35 is a previously described
MLV gag–pol expression construct with a CCHC-to-SSHS
mutation in NC (Zhang et al., 2002). This mutant displays
robust virion production but cannot support virus replication
effectively because of a defect in viral RNA encapsidation into
virions. pSΔPY is an SNV-based gag–pol expression constructFig. 1. Expression constructs used to examine functional complementation of
heterologous Gag proteins. (A) Structures of the gag–pol expression constructs.
MLV- and SNV-derived sequences are shown as white and gray boxes,
respectively. Construct pWZH35 contains a mutation in NC (shown as N*), in
which the conserved CCHC motif was changed to SSHC. Construct pSΔPY
contains a deletion mutation in which the PPPPYmotif (amino acids 40 to 44) in
the p18 domain was removed. (B) MLV vector titers generated by various
gag–pol expression constructs in one round of virus replication. Viral titers
are shown as CFU/ml (mean±standard deviation). Results shown are
summarized from three independent sets of experiments.with a deletion of the PPPPY sequence in the p18 domain of
Gag (Fig. 1A).
To examine their phenotypes, the mutant gag–pol expression
constructs were transiently transfected into SR2-293T cells
along with pSV-a-MLV-env, which expresses amphotropic
MLV Env. SR2-293T cells are a pool of 293T cells containing
proviruses from the MLV vector SR2 (Cheslock et al., 2000).
SR2 does not express viral proteins but encodes the hygromycin
phosphotransferase gene (hygro), which confers resistance to
hygromycin, and the green fluorescence protein gene (gfp).
Viruses were harvested from the transfected cells and used to
infect target D17 cells; the resulting SR2 titers were determined
by the number of hygromycin-resistant colonies. The SR2 viral
titers generated by any of the mutant constructs were at least
1000-fold lower than that of pWZH30 (Fig. 1B). As a negative
control, SR2-293T cells were transfected with only pSV-a-
MLV-env (shown as Mock). Western analyses were performed
to examine the expression of viral proteins in the transfected
cells and cell-free supernatants. Antibodies against MLV MA,
MLV CA, and SNV CA were used individually or in
combination to detect viral proteins in cell or virus lysates.
For all of the constructs shown in Fig. 1A, Gag expression was
detected in transfected cell lysates (data not shown).
The presence of homologous MA, p12/p18, or NC is not
sufficient to mediate functional MLV and SNV Gag/Gag–Pol
complementation
We first tested whether an MLV NC mutant (pWZH35) and
an SNV late-domain mutant (pSΔPY) could complement one
another and rescue viral titers (shown as pair 1 in Fig. 2A). We
cotransfected these two mutant gag–pol expression constructs
along with an env expression construct into SR2-293T cells and
determined the SR2 titers generated by the resulting viruses.
The resulting viruses generated SR2 titers of approximately 102
CFU/ml, which were similar to the sum of the SR2 titers
generated by the two vectors independently and far lower than
the wild-type viral titers (pWZH30, 105 CFU/ml). We also
tested the complementation of a pair of chimeric gag-encoding
vectors, pM/Sp18 and pS/Mp12 (Fig. 2A, pair 2), that do not
contain any homologous Gag domains; the viral titers generated
by this pair of vectors were also much lower than the wild-type
viral titers. These results indicate that without a homologous
domain(s), coexpression of mutant or chimeric MLV and SNV
Gag/Gag–Pol does not rescue the viral titers to the levels of the
wild-type viruses.
To test whether it is possible to achieve viral titers at levels
comparable to those of the wild-type viruses via complementa-
tion, we cotransfected two constructs that share three common
Gag domains: MA, CA, and NC (Fig. 2A, pair 3). The resulting
viruses indeed have titers comparable to those of wild-type
viruses, indicating that element(s) important for functional
coassembly and complementation reside in these three
domains. Additionally, these results indicate that homologous
p18 or p12 is not required for coassembly of heterologous Gag
proteins and functional complementation of viral proteins for
vector replication.
Fig. 2. Complementation of various gag–pol expression constructs as indicated
by MLV vector titers in one round of vector replication. (A) A homologous CA
domain is required for successful complementation that generates high vector
titers. (B) A homologous CA domain is not sufficient for successful
complementation. Results shown are summarized from three independent sets
of experiments.
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cannot coassemble because these two proteins are targeted to
different regions of the plasma membrane (Bennett and Wills,
1999). Thus, it is possible that MLVand SNV Gag proteins are
targeted to different parts of the plasma membrane, thereby
affecting efficient coassembly and complementation. Because
MA plays a critical role in directing Gag membrane targeting,
we examined whether MLV and SNV Gag chimeras with ahomologous MA domain could mediate efficient complementa-
tion by cotransfecting pM/Sp18 and pM/SCANC (Fig. 2A, pair
4). The viral titers generated by pair 4 were comparable to those
produced by pairs 1 and 2, indicating that homologous MA
alone is not sufficient to mediate efficient complementation. We
then tested the effects of homologous MA and NC (Fig. 2A, pair
5), or homologous p18 and NC (Fig. 2A, pair 6), and found that
neither pair produced viral titers comparable to those of wild-
type viruses. Taken together, these results indicated that the
presence of homologous MA, p18, and/or NC was not sufficient
for functional coassembly and complementation of MLV and
SNV Gag proteins to achieve wild-type viral titers, and
suggested that CA plays an important role in these interactions.
A homologous CA domain is critical for functional MLV and
SNV Gag/Gag–Pol complementation
To test the role of the CA domain in functional comple-
mentation of the MLVand SNV Gag proteins, we cotransfected
constructs that contained homologous MA and CA (Fig. 2A,
pair 7) or homologous CA and NC (Fig. 2A, pair 8). Viruses
derived from pair 7 or pair 8 had viral titers comparable to those
of wild-type viruses, indicating successful complementation.
Because pairs 7 and 8 both have a homologous CA domain, we
questioned whether a homologous CA domain alone is
sufficient for mediating functional complementation. To answer
this question, we cotransfected constructs that shared only an
MLV CA domain (Fig. 2A, pair 9) or an SNV CA domain (Fig.
2A, pair 10), and observed that viruses generated from either
pair had viral titers similar to those of wild-type viruses. To
further confirm the role of the CA domain in functional
complementation, we cotransfected vectors containing homo-
logous MA, p12, and NC domains but heterologous CA
domains (Fig. 2A, pair 11); the viral titers from viruses
generated by pair 11 were similar to those of pairs 1 and 2, in
which the two constructs did not contain homologous domains.
Taken together, these results indicate that a homologous CA
domain is necessary for efficient coassembly and complementa-
tion of MLV and SNV polyproteins.
Coassembly and functional complementation of viral proteins
from different expression constructs resulted in the rescue of
the viral titers
As shown in Fig. 2A, cotransfection of two gag–pol
expression vectors could significantly rescue the MLV vector
titers. Most likely, the rescued viral titers were a consequence of
the functional complementation of the coassembled viral
proteins. However, to rule out the remote possibility that protein
complementation occurred between coinfected viruses and not
from viruses with coassembled proteins, we performed the
following experiments. We selected the two constructs used in
pair 3 in Fig. 2A and generated viruses derived from pM/Sp18 or
pWZH35 individually, used these two viruses for coinfection,
and measured the viral titers. This coinfection resulted in viral
titers of 102 CFU/ml (Fig. 3), which are similar to titers
generated by each construct alone and very different from the
Fig. 3. MLV vector titers from coinfection of two virus stocks that were each
derived from a singly transfected gag–pol expression construct. Results shown
are summarized from three independent sets of experiments.
Fig. 4. Structures of constructs used in the BiFC assay to examine Gag–Gag
interactions in cells. MLVand SNV Gag sequences are shown as white and gray
boxes, respectively. Human cd8 is shown as a hatched box whereas the hinge
region and yfp sequences are shown as stippled boxes.
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allow coassembly to occur (Fig. 2A, pair 3). Similar results were
obtained (Fig. 3) using other pairs of constructs including those
used in pairs 7 and 9 in Fig. 2A. Taken together, these results
indicate that the rescue of the viral titers resulted from
complementation between coassembled proteins, and not from
complementation between coinfected viruses.
Homologous CA is necessary but not sufficient for functional
complementation of MLV and SNV Gag proteins—homologous
p12/p18 and CA are required for virus replication
Although we demonstrated that a homologous CA domain is
necessary for functional complementation of MLV and SNV
Gag polyproteins, it was unclear whether homologous CA is
sufficient to mediate such complementation. In order to rescue
the viral titers, functional complementation of the heterologous
Gag proteins requires coassembly of the heterologous proteins,
proper processing of the coassembled proteins, and compatible
mature proteins to support the early events of virus replication.
Previously, using MLV/SNV chimeras, we demonstrated that
homologous p12 and CA are required for efficient MLV
replication, probably because these two proteins act coopera-
tively to complete the early steps of viral infection (Lee et al.,
2005). Therefore, we hypothesized that sharing the homologous
CA between MLV and SNV Gag proteins is necessary but not
sufficient for coassembly and functional complementation
because other factors, such as the presence of homologous
p12/p18 and CA, are also required. To test our hypothesis, we
cotransfected two gag–pol expression constructs that both
contain MLV p12 and SNV CA. We found that the viruses
generated from such cotransfection did not restore MLV vector
titers (Fig. 2B, pM/SCA and pS/Mp12); we also observed
similar results from cotransfection of two gag–pol expression
constructs that both contained SNV p18 and MLV CA (Fig. 2B,
pM/Sp18 and pS/MCANC). These data are in sharp contrast to
those obtained from cotransfection of vector pairs 3 and 7–10 in
Fig. 2A, which recovered wild-type level viral titers. Theimportant determinant is that in the aforementioned pairs in
Fig. 2A, one of the vectors contained p12/p18 and CA from the
same virus, whereas in the two pairs in Fig. 2B, both vectors
contained p12/p18 from one virus and CA from another virus.
These findings confirm our previous observation that homo-
logous p12/p18 and CA are needed for efficient MLV
replication, and demonstrate that homologous CA is necessary
but not sufficient for functional coassembly and complementa-
tion of MLV and SNV Gag proteins.
Interactions and coassembly of MLV and SNV Gag proteins
The work described above indicated that CA plays a very
important role in the functional complementation of MLV and
SNV Gag proteins. Recent work on the coassembly of HIV-1
and RSV Gag indicated that homologous CA is required for the
colocalization and coassembly of the heterologous Gag
proteins. In our system, it was unclear whether homologous
CA is required for the coassembly of the MLV and SNV Gag
polyproteins, or is needed at a later stage during the replication
of the coassembled virions.
To examine whether MLVand SNV Gag proteins colocalize
and interact in cells, we performed the bimolecular fluorescence
complementation (BiFC) assay on these proteins (Hu and
Kerppola, 2003). In this assay, a fluorescent protein gene, such
as the venus yellow fluorescence protein gene (yfp) (Nagai et
al., 2002), was split into N-terminal (ny) and C-terminal (cy)
portions and fused to proteins of interest. Neither the NY nor the
CY portion of the YFP can confer fluorescence by itself. If the
proteins of interest interact with each other and bring the NY
and CY portions together, then fluorescence can be detected. If
the two proteins of interest do not interact with each other,
fluorescence is not detected.
We fused MLV gag to ny and cy to generate m-gag-ny and
m-gag-cy, respectively (Fig. 4). Neither construct alone could
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when m-gag-ny and m-gag-cy were coexpressed, MLV Gag–
Gag interaction allowed the complementation of NY and CY,
thereby generating the YFP fluorescence signal (Fig. 5A, left
panel). Similarly, coexpression of SNV gag fused to ny or cy (s-
gag-ny and s-gag-cy) also generated YFP fluorescence signals
(Fig. 5A, right panel). To test whether the YFP fluorescence
signals were generated by specific protein–protein interactions,
we used BiFC to examine the interactions between SNV Gag
and a cell surface protein, human CD8 α unit (CD8) (Moody et
al., 2001). In these experiments, a plasmid expressing red
fluorescence protein gene (rfp) (Campbell et al., 2002) was
added and used as a transfection control. We generated cd8-nyFig. 5. Analyses of Gag–Gag interaction by the BiFC assay. (A) Interactions of
homologous Gag. (B) Interactions between CD8 and CD8, and SNV Gag and
CD8. These samples were cotransfected with a plasmid that expresses rfp,
which served as a transfection control. (C) Interactions between heterologous
Gag proteins. Bar = 10 μm.and cd8-cy constructs (Fig. 4). Human CD8 α unit is known to
dimerize; upon coexpression of cd8-ny and cd8-cy, we observed
YFP fluorescence signals (Fig. 5B, upper left panel). However,
when cd8-ny and s-gag-cy were coexpressed, YFP fluorescence
signals were not detected, although the RFP fluorescence signal
was detected, indicating successful transfection (Fig. 5B, lower
panels). Coexpression of cd8-cy and s-gag-ny, or coexpression
of cd8-ny and m-gag-cy also failed to produce detectable YFP
fluorescence signals (data not shown). These results indicated
that BiFC can easily detect interactions between homologous
Gag proteins, and the fluorescence signals detected were based
on protein–protein interactions and not from nonspecific signals
due to coexpression of ny and cy fusion proteins.
We then examined coexpression of two pairs of constructs
containing chimeric or mutant gag genes. We generated
constructs m-NC*-ny, m-Sp18-cy, and m-SCA-cy (Fig. 4),
which contained the gag sequences of pWZH35, pM/Sp18, and
pM/SCA, respectively. Coexpression of pWZH35 and pM/Sp18
resulted in successful complementation (Fig 2A, pair 3); as
expected, we detected YFP fluorescence signals when m-NC*-
ny and m-Sp18-cy were coexpressed (Fig. 5C, top left panel).
Coexpression of pWZH35 and pM/SCA did not result in
successful complementation (Fig. 2A, pair 11). However,
abundant YFP fluorescence signals were detected when m-
NC*-ny and m-SCA-cy were coexpressed (Fig. 5C, top right
panel), indicating that these Gag proteins can interact despite
their different CA domains. To further determine whether a
homologous CA domain or any homologous domain was
required for interactions between these heterologous Gag
proteins, we coexpressed m-gag-ny and s-gag-cy that contained
MLV and SNV Gag, respectively, and observed abundant YFP
fluorescent signals (Fig. 5C, bottom panel). These data
indicated that MLV and SNV Gag proteins can colocalize and
interact in cells. Therefore, the requirement for homologous CA
domain is likely to occur at a postassembly step(s).
Discussion
In this study, we investigated the requirements for functional
complementation of Gag proteins from MLV and SNV, two
genetically distinct gammaretroviruses. We used mutant or
chimeric Gag proteins that could not efficiently support MLV
vector replication, and tested whether two Gag proteins can
functionally complement each other by the restoration of vector
titers. We found that MLVand SNVmutant Gag proteins did not
complement each other, whereas coexpression of chimeric Gag
polyproteins containing the same CA domain could restore
MLV vector titers. We then explored whether the homologous
CA domain is required for the colocalization of heterologous
Gag proteins, and found that SNV and MLV Gag proteins
colocalize and interact in cells. From these results, we conclude
that homologous CA domains are required for functional
complementation of MLV and SNV Gag polyproteins and the
requirement for homologous CA most likely occurs at a
postassembly step(s).
A homologous N-terminal MA domain was needed for the
coassembly of MLV and RSV Gag proteins, suggesting that
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plasma membrane (Bennett and Wills, 1999). Previous studies
indicated that membrane targeting is a prerequisite for Gag
multimerization in both MLV and SNV (Schultz and Rein,
1989; Weaver and Panganiban, 1990). Our BiFC data
demonstrated colocalization and interaction between MLV and
SNV Gag proteins (Fig. 5C). In addition, our complementation
results demonstrated that Gag with SNV MA and Gag with
MLV MA could coassemble and generate infectious viruses
(Fig. 2A, pairs 8–10). Taken together, these two lines of results
indicate that MLV and SNV Gag proteins are targeted to the
same locations of the plasma membrane during virus assembly.
In contrast to the coassembly of RSV and HIV-1 Gag
proteins, a homologous CA domain is not needed for MLVand
SNV Gag proteins to colocalize and interact with each other.
Our observation also revealed that Gag proteins with and
without the charged assembly helix (CAH) motif could interact.
We previously described the CAH motif in MLV CA as a
critical factor for proper assembly of the virus particle
(Cheslock et al., 2003). This predicted helical motif is located
at the C terminus of MLV CA. Deletions or other mutations that
disturb the phases of the helices cause MLV assembly defects
that can be identified phenotypically by drastic reduction of
particle production and the formation of mutant virions with
aberrant sizes and RNA content (Cheslock et al., 2003). The
CAH motif is conserved among most gammaretroviruses, but
not in SNV (Cheslock et al., 2003). Therefore, although CAH is
strictly required for proper MLV virus assembly, interactions
can occur between Gag with CAH and Gag lacking the CAH
motif.
CA plays multiple roles during retrovirus replication. As a
domain, CA plays an important role in virus assembly; as a
mature protein, CA forms the virion core, participates in the
uncoating process, and possibly plays a role in reverse
transcription and the transport of the replication complex
(Alin and Goff, 1996; Cairns and Craven, 2001; Lee et al.,
2005; Swanstrom and Wills, 1997). Among the MLV and SNV
Gag domains, CA has the highest identity (42%) in amino acid
sequence; the identities of MA, p12/p18, and NC are 31%, 23%,
and 33%, respectively. There are certain similar features in the
MLV and SNV CA sequences. Besides the major homology
domains located near the central part of CA, there are patches of
similar sequences elsewhere in CA; for example, the amino acid
sequence in a part of the conserved α-helical structures, such as
α3, is identical in MLV and SNV (Fu et al., 2006). Similar to
HIV-1 CA, the mature MLV CA refolds after proteolytic
cleavage and generates the β1–β2 N-terminal hairpin loop,
which is critical for CA–CA interaction; this refolding is
thought to involve the formation of a salt bridge between Pro 1
and Asp 54 in MLV CA (Mortuza et al., 2004). Interestingly,
SNV CA also has Pro 1 and an equivalent Asp 60, which is
embedded in the conserved α3 in a manner identical to MLV
Asp 54. This sequence conservation suggests that a similar
hairpin loop is also formed in mature SNV CA. Despite these
conserved features between MLV and SNV CA, it is unclear
whether these two mature CA proteins can properly interact
with each other to form the virus core. Further studies arerequired to delineate the precise motif(s) or structure(s) that lead
to the requirement for the same CA.
To our knowledge, there are three other studies examining
elements needed for coassembly of heterologous Gag proteins.
The previous studies using MLVand RSV, and RSVand HIV-1
used viruses from different genera. In both cases, a homologous
domain is needed for coassembly of the viral proteins. We have
performed this study and a separate study examining the
interactions of Gag proteins from viruses of the same genus. In
both studies, we found that the heterologous Gag proteins can
colocalize and interact. In our study of the interactions of HIV-1
and HIV-2 Gag proteins, we found that these Gag proteins can
coassemble and some mutants can functionally complement
each other (Boyko et al., 2006). In the current study, we found
that although MLV and SNV Gag proteins can interact, a
homologous CA domain is needed for functional complementa-
tion of the two Gag proteins. Taken together, these studies
indicate the different levels of interactions between hetero-
logous Gag proteins and different barriers presented in the
coassembly and functional complementation of the hetero-
logous Gag proteins. One of the implications of coassembly of
viral proteins is a potential to alter the property of the
phenotypically mixed particles and provide a possible gateway
for viruses to adapt to a new environment and to evolve.
Therefore, our work not only has revealed elements important
for coassembly and complementation of heterologous Gag, but
also has important implications in virus evolution.
Materials and methods
Plasmid construction
Standard cloning procedures were used to construct all
plasmids (Sambrook et al., 1989). The previously described
plasmid pWZH30 (Zhang et al., 2002) was derived from pLGPS
(Miller and Buttimore, 1986) and expresses MLV gag–pol from
a truncated MLV 5′ long terminal repeat (LTR) but lacks the
packaging signal and the 3′ LTR. Plasmid pRD136 has also
been described (Martinez and Dornburg, 1995) and expresses
SNV gag–pol.
All the mutant or chimeric gag–pol expression constructs
were generated by overlapping PCR and cloning of the PCR
fragments. To ensure that inadvertent mutations were not
introduced into these chimeras or mutants, the sequences of all
regions subjected to PCR were confirmed by DNA sequencing.
Plasmids pM/Sp18, pM/SCA, and pM/SCANC have been
previously described (Lee et al., 2005). To generate pS/Mp12,
pS/Mp12CA, pS/Mp12CANC, pS/MCANC, and pSΔPY, two
PCR products were generated and later combined using
overlapping PCR. DNA fragments containing a hybrid or
mutant gag generated by overlapping PCR were digested with
StuI and BlnI, and inserted into StuI–BlnI digested pRD136.
Plasmids pM/SNC, pS/MNC, and pWZH35 have been
described previously (Certo et al., 1999; Zhang et al., 2002).
All constructs used for the BiFC assay were derived from
two expression vectors, HIV-2 gag-ny and HIV-2 gag-cy
(Boyko et al., 2006). These constructs are HIV-1 based and
395S.-K. Lee et al. / Virology 360 (2007) 388–397contain HIV-1 LTRs, 5′ untranslated region, and truncations in
pol, env, vif, vpr, and vpu; they also express HIV-1 tat, rev, and
nef. Additionally, these two constructs express HIV-2 gag fused
to either the ny portion or the cy portion of YFP. The ny portion
contains amino acids 1–172 and the cy portion contains amino
acids 173–238 of YFP; a hinge region is located between the
gag and yfp sequences. DNA fragments containing various
gag genes were amplified by PCR, digested with PauI and
XmaI, and cloned into the PauI–XmaI-digested HIV-2 gag-ny
or HIV-2 gag-cy constructs to replaced the HIV-2 gag in these
constructs. The resulting constructs express various gag genes
fused in-frame to ny or cy portions of yfp. Previously described
cd8-ny and cd8-cy have the same structures, except that gag
was replaced by the human CD8 α unit gene (cd8).
Cell culture, DNA transfection, and virus infection
D17 cells are dog osteosarcoma cells permissive to
amphotropic MLV infection (Riggs et al., 1974); 293T cells
are human embryonic kidney cells (DuBridge et al., 1987).
SR2-293T cells are a pool of 293T cells containing SR2
proviruses derived from the MLV-based vector pSR2 (Cheslock
et al., 2000), which expresses the hygromycin phosphotransfer-
ase B gene (hygro) (Gritz and Davies, 1983) and the green
fluorescent protein gene (gfp) (Chalfie et al., 1994). Cells were
maintained at 37 °C with 5% CO2 in Dulbecco's modified
Eagle's medium supplemented with 6% calf serum (D17) or
10% fetal calf serum (293T) in the presence of penicillin (50
U/ml) and streptomycin (50 μg/ml). Transfection was per-
formed using the calcium phosphate precipitation method
(Sambrook et al., 1989) (MBS transfection kit, Stratagene)
with a mixture of DNA containing the gag–pol expression
construct and pSV-a-MLV-env at a 5:1 (w/w) ratio, respectively.
Plasmid pSV-a-MLV-env expresses amphotropic MLV env
(Landau et al., 1991). To examine whether two Gag proteins can
functionally coassemble, SR2-293T cells were cotransfected
with the same amount of each gag–pol expression construct.
Viruses were harvested 48 h posttransfection and filtered
through a 0.45-μm-pore-size membrane (Millipore) to remove
cell debris. Serial 10-fold dilutions of the virus samples were
used to infect D17 cells in the presence of Polybrene (50 μg/ml
final concentration). Infected cells were selected with hygro-
mycin (120 μg/ml final concentration), and viral titers were
determined by scoring the number of hygromycin-resistant
colonies. For coinfection, the same volume of each virus
supernatant was mixed, diluted serially, and used to infect D17
cells in the presence of Polybrene (50 μg/ml final concentration).
Western analyses and reverse transcriptase (RT) assays
Viruses were concentrated by ultracentrifugation at
25,000 rpm for 90 min at 4 °C using a TH-641 rotor (Sorvall);
pelleted viruses were then resuspended in phosphate-buffered
saline for Western analyses and RT assays. Viral proteins in
virions or in transfected cells were examined by Western
analyses using polyclonal rabbit anti-MLV-CA, anti-MLV-MA
(a kind gift from the AIDS Vaccine Program, SAIC-Frederick),or anti-SNV-CA (a kind gift from Nancy Rice, NCI-Frederick)
antibodies. RT assays were performed using standard proce-
dures (Cheslock et al., 2000; Temin and Mizutani, 1970).
Confocal microscopy
Plasmid DNAs were transfected into HeLa cells or 293T
cells, and images were collected on a Zeiss 510 META confocal
microscope with Plan-Neofluar 40 X/N.A. 1.3 Oil DIC
objective, 488 nm or 514 nm, and 543 nm laser excitation
lines and the emission window of 527–559 nm for the venus
YFP signals and 602–655 nm for RFP signals, respectively. The
images were processed using Zeiss LSM 5 Image Browser and
Adobe Photoshop 7.0.1. software.
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